Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
Iván ChiviteLeire BerrocalElisa de LazzariSoodabeh NavadehCarla Lluis-GanellaAlexy InciarteLorena de la MoraAna González-CordónMaria Martínez-RebollarMontserrat LagunoBerta TorresJosé Luis BlancoEsteban MartinezJosep MallolasJuan AmbrosioniPublished in: The Journal of antimicrobial chemotherapy (2024)
Real-world studies demonstrate low discontinuation rates and high rates of virologic suppression in individuals treated with BIC/FTC/TAF, both TN and TE with and without previous detection of M184V substitution.